The American biotechnology company has announced that its vaccine against Covid-19 is 94.5% effective.
News for hope related to the fight against the pandemic that is ravaging our planet and which is affecting the coronavirus has changed our lives . That is why several pharmaceutical companies are looking hard for the vaccine that can put an end to this evil.
After Pfizer, which one was the first to achieve a 90% of efficacy according to proven results, it now appears Moderna confirming that its vaccine against Covid-19 has 94.5% effective against the coronavirus.
The American company announced this via a press release stating that a trial for more than 30,000 people, injecting half of them with the vaccine and the other half with a placebo. They highlight that 7,000 people were over the age of 65 and 5,000 were younger, although with chronic illnesses linked to a greater risk of infection from Covid-19, for a total of 42% of the at-risk group.
When will it be available, how much will it cost and how and where to get it
Salvador Illa, Minister of Health, has already set a date for the start of vaccination in Spain. “Vaccination in Spain will begin on December 27 after we received the first doses of the Pfizer vaccine the day before. Weekly doses will be received that will be distributed equitably among the Autonomous Communities and administered as determined in the national strategy. is the beginning of the end of the pandemic, but it is not the end. We will have to continue to take measures and continue to take responsibility,” says Illa.
The vaccine comes in two doses 28 days apart and is said to cost $25, about $21 to exchange, according to the company’s technical director, Juan Andrés, in statements to El País.
“We are getting a vaccine that can stop Covid-19,” said Stephen Hoge, president of the pharmaceutical company.
The prediction is that there are 20 million doses ready to be distributed in the United States, a figure that would reach 500 to 1,000 million vaccines globally and by 2021.
The company, with two supply chains in the United States and Europe, has reported effects such as injection site pain (in 2.7% of vaccinees), fatigue (nearly 10%), joint pain (5%), and headache (4.5 %). %). “These are the symptoms one has with a moderate flu.”
They estimate that it can be a stable vaccine at temperatures of 2 to 8 degrees and can be kept for 30 days, although it can be stored for six months at a temperature of -20 degrees.
However, it is not the only option, China, Spain, Australia, the United States, Germany (of Dietmar Hopp the hated owner of the Hoffenheim to the head) and England they are working on forced marches, with the latter apparently having the advantage. members of the Jenner Institute belonging to the Oxford university assured that their hypothetical vaccine (called hAdOx1 nCoV-19) has reached a critical stage with Positive results : healed six resu macaques the animal most closely resembling humans from a biological point of view.
Now it was CureVac, Hopp’s, who reported “positive preclinical results at low doses.” What follows, as announced, are the human testing .
The University of Oxford, in conjunction with the pharmaceutical AstraZeneca, reported that the test was safe in more than 1,000 people and that he developed immunity in late July. The two entities had said the results are promising, although they announced on September 8 the temporary suspension of tests due to “possible side effects” in one of the volunteers who received the dose in the UK. While the news caused alarm, the scientific community clarified that it is a matter of protocol, which is common in this type of research. Although it was initially speculated that the drug would be available in September 2020 ; we will definitely have to wait a little longer.
Source: Goal